



# Clover Biopharmaceuticals, Ltd.

## 三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock Code 股份代號: 2197)

23 February 2024

Dear registered shareholder(s),

### Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023 and the articles of association of the Company, Clover Biopharmaceuticals, Ltd. (the “Company”) is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “Corporate Communications”), which means any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at [www.cloverbiopharma.com](http://www.cloverbiopharma.com) and the HKExnews website at [www.hkexnews.hk](http://www.hkexnews.hk) in place of printed copies.

To support environmental protection and enhance efficient communication with you, the Company encourages you to access the Corporate Communications via the Company’s or HKEx’s website instead of receiving printed copies by mail.

### Solicitation of electronic contact details

To make your election, please mark (✓) in the appropriate box on the enclosed reply form (the “Reply Form”) on the reverse side, and fill in the necessary information and then sign and return the Reply Form to the Company’s Hong Kong share registrar (the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, or return the Reply Form by sending an email to [clover.ecom@computershare.com.hk](mailto:clover.ecom@computershare.com.hk).

By electing and marking (✓) on PART A of the Reply Form and providing your email address, you have expressly consented to the arrangement of electronic dissemination of the Corporate Communications. To ensure timely receipt of the Actionable Corporate Communications<sup>(Note)</sup>, the Company recommends you to provide your email address by filling in and returning the Reply Form to the Share Registrar at the abovementioned address or by email. **If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications<sup>(Note)</sup> in printed form in the future.**

If you want to receive the Corporate Communications in printed form, please mark (✓) on PART B of the Reply Form, and complete and return the Reply Form on the reverse side to the Share Registrar or send an email to [clover.ecom@computershare.com.hk](mailto:clover.ecom@computershare.com.hk) specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

If the Company does not receive the duly completed and signed Reply Form, the Company will send the future Corporate Communications (including Actionable Corporate Communications) in printed form to you by post at your address as appearing in the Company’s register of members maintained by the Share Registrar.

Should you have any queries relating to this letter, please call the service hotline of the Share Registrar at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m. (Hong Kong time), Monday to Friday, excluding Hong Kong public holidays).

By order of the Board  
Clover Biopharmaceuticals, Ltd.  
Dr. Peng LIANG  
Chairman of the Board

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

各位登記股東：

### 以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則（「上市規則」）第 2.07A 條及本公司之組織章程細則，三葉草生物製藥有限公司（「公司」）謹此通知 閣下，公司已採用以電子方式發布公司通訊（「公司通訊」）之安排，該公司通訊是指公司向向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函；和 (f) 委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 [www.cloverbiopharma.com](http://www.cloverbiopharma.com) 和披露易網站 [www.hkexnews.hk](http://www.hkexnews.hk) 上提供，以代替印刷本。

為支持環保及促進與 閣下之有效溝通，本公司鼓勵及推薦 閣下透過本公司網站及香港交易所網站瀏覽公司通訊以代替通過郵件收取印刷本。

### 徵集電子聯絡資料

在行使選擇權時，請 閣下於本函背頁之回條（「回條」）上適當的空格內劃上「✓」號，並在回條上填寫所需資料及簽名，然後把回條交回公司的香港股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓，或發送電子郵件至 [clover.ecom@computershare.com.hk](mailto:clover.ecom@computershare.com.hk)。

透過選擇回條甲部並劃上「✓」號，並提供電子郵件地址， 閣下已明示同意以電子方式發布公司通訊之安排。為確保及時收到可供採取行動的公司通訊<sup>(附註)</sup>，公司建議 閣下透過填寫回條提供 閣下的電子郵件地址並按上述地址或以電子郵件方式交回股份過戶登記處。**如果公司沒有收到 閣下的有效電子郵件地址，直至股份過戶處收到 閣下有有效的電子郵件地址前，本公司未來將以印刷本形式發送可供採取行動的公司通訊<sup>(附註)</sup>。**

若 閣下希望收取公司通訊之印刷版，請選擇回條乙部並劃上「✓」號填妥本函背頁之回條並交回股份過戶處，或發送電子郵件至 [clover.ecom@computershare.com.hk](mailto:clover.ecom@computershare.com.hk)，並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意，收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效，此後將過期。

如果公司沒有收到 閣下已填妥並簽署的回條，本公司將根據股份過戶處所存置的股東名冊上所示的地址透過郵寄方式向 閣下寄送未來的公司通訊（包括可供採取行動的公司通訊）的印刷本。

如 閣下對本函件有任何疑問，請於辦公時間內（星期一至星期五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間））致電證券登記處熱線(852) 2862 8688 查詢。

承董事會命  
三葉草生物製藥有限公司  
董事長  
梁朋博士

2024 年 2 月 23 日

附註：可供採取行動的公司通訊指任何涉及及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利的公司通訊。

